In the News
China—A new era of drug development and innovation
Albert Tsai discusses how Chinese biotech companies are emerging as serious competitors in the global market.
More than a business, PPD seeing growth at its drug testing complex
Over the last 30+ years, PPD’s bioanalytical lab in Richmond, Virginia, has grown to become one of the largest labs of its kind in the world.
Four Key Questions About Patient Experience in 2019
PM360 asked those with expertise in crafting better experiences for patients key questions about how companies must change to better serve patients.
Incorporating the patient voice in clinical trials ‘mandates time and thoughtful consideration of every stakeholder’
Incorporating patient insights into clinical trial design has ‘consistently’ shown to improve timelines.
Flex your outsourcing model to maximize drug development
Timothy King discusses the rationale, advantages and disadvantages behind strategically selecting the right outsourcing model.
PPD picks up Bioclinica’s global site business
AES has acquired the clinical research site business of Bioclinica, expanding AES’ global footprint and solidifying its leadership position in patient access and site conduct.
PPD signed on as preferred provider for Harbour BioMed
Harbour BioMed (HBM) and PPD have announced a strategic collaboration to develop HBM’s innovative therapeutics in the fields of oncology and immunology.
PPD extends Japanese footprint with exclusive collaboration
Evidera has entered into an exclusive collaboration agreement with Clinical Study Support, Inc., extending both organizations’ capabilities to deliver more robust consulting and analytical capabilities.
PPD Collaborates With Biopharma Company On Oncology, Immunology Therapies
Harbour BioMed (HBM) has selected PPD as its preferred global contract research partner to conduct clinical studies on its internal research pipelines.
